Background: The aim of this study was to construct a novel prediction model for the pathological complete response ( pCR) to neoadjuvant chemotherapy (NAC) using immune-related gene expression data.
introduction Recently, an increasing number of breast cancer patients have been treated with neoadjuvant chemotherapy (NAC) to improve not only the operability of locally advanced breast cancer but also the feasibility of breast-conserving surgery for patients with a relatively large tumor. In addition, NAC yields important prognostic information, i.e. a pathological complete response ( pCR) after NAC is strongly correlated with excellent prognosis [1] . Currently, sequential chemotherapy with taxane and anthracycline-based regimens is most commonly used in NAC in clinical practice, but the pCR rate for these regimens is not very high (in the range of 10-30%) [2] . It therefore appears important to develop a predictive factor for pCR that could aid decision-making process concerning the indication for NAC.
Various pathological factors, such as negative estrogen receptor (ER), high-Ki67 index, high histological grade (HG) and positive human epidermal growth factor receptor 2 (HER2), have been repeatedly shown to be significantly associated with pCR. In addition, several models for the prediction of pCR have been developed using gene expression analysis with DNA microarrays or other techniques [3] . However, these predictive factors or models are not sufficiently powerful to be incorporated into clinical practice.
Recently, Iwamoto et al. [4] , who performed a pathway analysis based on gene expression data from DNA microarrays, identified the importance of immune-related pathways in the prediction of pCR. More recently, Denkert et al. [5] reported that tumorinfiltrating lymphocytes (TILs) are associated with a favorable response to NAC, and Schmidt et al. [6] found that an immunerelated signature, which is represented by an IGKC-positive lymphocyte, is important for the prediction of pCR. The aim of our study was therefore to construct a novel prediction model for NAC that focuses on immune-related genes.
patients and methods patients and tumor samples
In this study, 117 breast cancer patients (stages II and III) were retrospectively recruited. These patients had been treated with NAC consisting of paclitaxel (Bristol-Myers Squibb Co., New York, USA) 80 mg/m 2 weekly for 12 cycles followed by combined 5-fluorouracil (Kyowa Hakko Kirin Co., Tokyo, Japan) 500 mg/m 2 , epirubicin (Nippon Kayaku Co., Tokyo, Japan) 75 mg/m 2 and cyclophosphamide (Shionogi & Co., Osaka, Japan) 500 mg/ m 2 every 3 weeks for four cycles (P-FEC) at Osaka University Hospital (OUH) between 2002 and 2010. The patients treated with neoadjuvant trastuzumab or hormonal therapy were excluded from the study. Before NAC, all of the patients underwent a tumor biopsy with a vacuum-assisted corebiopsy instrument (Mammotome 8G; HH Ethicon Endosurgery/Johnson and Johnson Company, Langhorne, PA) under ultrasonographic guidance for histological examination and gene expression analysis. The tumor samples for histological examination were fixed in 10% buffered formaldehyde, and the tumor samples for gene expression analysis were snap-frozen in liquid nitrogen and stored at −80°C until use. Informed consent for the study was obtained from all the patients before the tumor biopsy.
RNA extraction and DNA microarray analysis
The RNA extraction and DNA microarray analysis (Human Genome U133 plus 2.0 Array; Affymetrix, Santa Clara, CA) were conducted as described previously [7] . The presence of tumor cells in the biopsy samples was estimated through the histological confirmation of their presence in the adjacent tumor biopsy samples, regardless of the percentage of tumor cells in the histological section.
histological evaluation of the response to chemotherapy
The surgical specimens were cut into 5-mm slices, and hematoxylin and eosin-stained 3-μm sections were prepared to determine the presence or the absence of tumor cells. The complete disappearance of invasive tumor cells in the breast and negative lymph node were defined as pCR, regardless of the presence or the absence of ductal carcinoma in situ in the breast.
immunohistological examination
The ER and Ki67 levels in the tumor biopsy samples were determined immunohistochemically as described previously [7] . The cut-off values for ER and Ki67 were 10 and 20%, respectively. The HER2 amplification was performed through fluorescence in situ hybridization (FISH) using the PathVysion HER-2 DNA Probe Kit (Vysis, Abbott Molecular Inc., Chicago, IL). A tumor was classified as HER2-amplified if the FISH ratio was ≥2.0. FOXP3 and CD8 were determined immunohistochemically as described previously (the 117 patients analyzed in the present study were included in a previous study involving FOXP3 and CD8 [8] ).
public datasets of NAC-treated patients
The patients who fulfilled the following inclusion criteria were selected from the public datasets (GEO, http://www.ncbi.nlm.nih.gov/geo/): (i) gene expression data were obtained using Affymetrix HG-U133; (ii) NAC consists of anthracycline-based regimens with or without antimicrotubule agents and does not include trastuzumab or hormonal therapy; (iii) information on the pathologically documented response is available and the definition of pCR is the same as described above and (iv) the quality of the gene expression data is sufficiently high. A total of 901 patients who fulfilled the above-mentioned criteria were selected from the six datasets (GSE16446 [9] , GSE20194 [10] , GSE20271 [11] , GSE22093 [12] , GSE23988 [4] and GSE41998 [13] ) (Table 1 ) and served as the external validation set.
construction of a prediction model for pCR
First, the 934 probes that are classified as 'immune response' in the Gene Ontology Biological Process from the HG-U133A annotation file (version na32; http://www.affymetrix.com/) were selected. The 117 patients treated at OUH were randomly divided into the training set (n = 58) and the internal validation set (n = 59) using the outcome-stratified randomization method (Table 1) such that the training set included double the number of pCR cases in the validation set in order to enhance the statistical power for the detection of the differentially expressed genes between the pCR and the non-pCR cases in the training set [14] . All remaining processes were executed by using the training set only. The expression of the 30 of 934 probes was found to be significantly (P < 0.010) different between the pCR and the non-pCR cases through Welch's t-test. Supervised analysis using DLDA (Diagonal Linear Discriminant Analysis) was employed for the construction of the prediction model using these probes. The sequential forward filtering method, which assesses the leave-one-out cross-validation, was employed to optimize the prediction model, and we found that the DLDA model comprising 23 probes (19 genes; supplementary Table S1 , available at Annals of Oncology online) exhibited the highest accuracy in the training set (supplementary Figure S1 , available at Annals of Oncology online) and was therefore adopted as the immune- The 901 samples in the external dataset were classified into luminal A, luminal B, HER2-enriched, basal-like and normal breast-like subtypes by PAM50 [15] . The normal breast-like tumor subtype was excluded from further analysis because this subtype contains only a small amount of tumor cells [16] . The genomic grade index (GGI) was calculated according to the method described by Sotiriou et al. [17] . Using IRSN-23, the patients were classified as either genomically predicted responders (Gp-R), who are likely to achieve pCR, or genomically predicted non-responders (Gp-NR), who are unlikely to achieve pCR. In the training set, the Gp-R showed a significantly higher pCR rate than the Gp-NR (62 versus 6%, P = 7.12E −06). The accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of IRSN-23 27  30  507  69  48  52  48  105  35  71  79  >50  31  29  394  45  34  35  43  116  26  46  49  cT  T0-1  2  3  59  16  3  5  8  22  2  2  1  T2  46  42  506  79  44  37  39  131  19  77  80  T3  9  9  222  5  21  18  19  34  40  38  47  T4  1  5 Negative  41  41  761  59  82  77  75  186  61  108  113  Positive  17  18  114  29  0  10  16  35  0  9  15  Unknown  0  0  26  26  0  0  0  0  0  0  0  HG  1  8  9  34  2  3  5  10  13  1  0  0  2  37  42  218  20  25  31  30  93  19  0  0  3  13  8  349  87  37  36  36  115  38  0  0  Unknown  0  0  300  5  17  15  15  0  3  117  128  pCR  Yes  18  9  198  16  24  7  19  45  20  34  33  No  40  50  703  98  58  80  72  176  41  83 were 79, 89, 75, 62 and 94%, respectively. The IRSN-23 model was then applied to the internal validation set, and the Gp-R showed a significantly higher pCR rate than the Gp-NR (38 versus 0%, P = 1.04E−04). In this set, the accuracy, sensitivity, specificity, PPV and NPV of IRSN-23 were 75, 100, 70, 38 and 100%, respectively. The heat maps were generated through the hierarchical cluster analysis using the genes included in IRSN-23 in the training and internal validation sets (supplementary Figure S2 , available at Annals of Oncology online).
relationships between IRSN-23 and clinic pathological parameters
The Gp-R were significantly more likely to be more than 50 years of age (P = 4.66E−04), lymph node metastasis-positive (P = 0.034), ER-negative (P = 4.54E−09), HG3 (P = 0.049) and Ki67-positive (P = 0.009) and to exhibit CD8-positive T-cell infiltration (P = 0.024) and FOXP3-positive T-cell infiltration (P = 8.27E−05) compared with the Gp-NR (supplementary Table S2 , available at Annals of Oncology online).
external validation of IRSN-23 using public datasets IRSN-23 was further evaluated using six external datasets (II validation set), which included 901 patients treated with NAC. Of these patients, 339 were classified as Gp-R, and 562 were classified as Gp-NR. The pCR rate for the Gp-R was significantly higher than that obtained for the Gp-NR (40 versus 11%; P = 4.98E−23), as shown in Figure 1 . The accuracy, sensitivity, specificity, PPV and NPV of IRSN-23 were 70, 68, 70, 40 and 89%, respectively. The multivariate analysis showed that IRSN-23 was the most significant [odds ratio (OR) = 4.6; 95% confidence interval (CI) = 2.7-7.7; P = 8.25E−09] predictor of pCR, followed by HER2 (P = 0.012), ER (P = 0.018) and HG (P = 0.049) ( Table 2 ).
prediction of pCR by IRSN-23 according to the intrinsic subtype
In the external validation set, the Gp-R showed a significantly higher pCR rate than the Gp-NR in the ER(+)/HER2(−), ER (−)/HER2(+) and ER(−)/HER2(−) subtypes, and a similar tendency was also observed in the ER(+)/HER2(+) subtype (Figure 2A ). In each intrinsic subtype determined by PAM50, the Gp-R showed a significantly higher pCR rate than the Gp-NR ( Figure 2B ).
prediction of pCR by IRSN-23 according to the NAC regimen
In the external validation set, the predictability of pCR by IRSN-23 was evaluated with respect to the different NAC regimens, which include epirubicin (n = 114), FAC (5-fluorouracil, doxorubicin and cyclophosphamide) or FEC (5-fluorouracil, epirubicin and cyclophosphamide) (n = 169), sequential anthracycline and paclitaxel (n = 429), sequential anthracycline and docetaxel (n = 61) and sequential anthracycline and ixabepilone (n = 128). As shown in Figure 2C , the Gp-R showed a significantly higher pCR rate than the Gp-NR for each regimen. Figure S3 , available at Annals of Oncology online). The Gp-R with a high GGI showed the highest pCR rate (31%), and the Gp-NR with a low GGI showed the lowest pCR rate (5%). The Gp-R with a low GGI (20%) and the Gp-NR with a high GGI (15%) showed intermediate pCR rates.
discussion
Because it is well known that TILs play a important role in the response to chemotherapy for breast cancer [5, 18] , it is assumed that the immune-related signature is also associated with the response to chemotherapy [6, 19, 20] . In the current study, we analyzed all of the immune-related genes to select those that differentially expressed in pCR and non-pCR and then used these selected genes to construct the IRSN-23 model using the training set, the diagnostic accuracy of which could be validated with the internal validation set. The IRSN-23 captures the true characteristics of TILs, as was verified through its significant association with the infiltration of CD8-positive T-cells (cytotoxic T-cells) and FOXP3-positive T-cells (regulatory T-cells, T-regs), both of which have been demonstrated to be significantly associated with pCR [8] . It is well known that non--biological experimental variations or batch effects are commonly observed across multiple batches of DNA microarray gene expression experiments, which often renders the analysis of the combined data from the multiple batches difficult [21] . Thus, our prediction model was initially constructed using our data (n = 117), which were obtained under the same experimental conditions to avoid any batch effects, rather than using the public datasets, although these included a much larger number of patients. The external validation of the IRSN-23 model was then performed using six public datasets (n = 901). The IRSN-23 model was able to classify the patients as either Gp-R or Gp- NR with pCR rates of 40 and 11%, respectively (P = 4.98E −23). The multivariate analysis showed that IRSN-23 was a highly significant (P = 8.25E−09) predictor of pCR and far superior to HER2 (P = 0.012), ER (P = 0.018) and HG (P = 0.049). Among the immune-related signatures that have been found for the prediction of the response to NAC to date, IRSN-23 appears to have the lowest P-value and the highest OR [6, 19] . Because it is well established that the intrinsic subtypes determined by PAM50 are significantly associated with pCR [22] , we also evaluated IRSN-23 for each intrinsic subtype and were able to show that IRSN-23 can predict pCR for each intrinsic subtype. It is noteworthy that IRSN-23 was able to predict pCR even for the luminal A subtype, even though no prediction model has yet been able to do so [19] . In addition, we were able to show that IRSN-23 can predict pCR regardless of the chemotherapeutic regimen. These results appear to indicate that IRSN-23 has a better predictive capability for pCR than the previously reported immune-related signatures and suggest that antitumor immunity is involved in the response to chemotherapy, regardless of the intrinsic subtypes or chemotherapeutic regimens. IRSN-23 includes CXCL9, which is significantly up-regulated in Gp-R. This observation is consistent with the report by Denkert et al. [5] , who found that CXCL9 expression is significantly associated with TILs and the response to NAC. IRSN-23 also includes IDO1, which inhibits the T-cell response by increasing the number of T-regs [23] . Wainwright et al. [24] reported that IDO deficiency reduces T-regs recruitment and enhances T-cell mediated immunity against brain tumors. The association of the intra-tumoral infiltration of T-regs with a good response to chemotherapy for breast cancer has also been reported by us and other investigators [8, 18] .
The clinical value of IRSN-23 appears to be limited because its diagnostic accuracy is not sufficiently high. We thus attempted to enhance its accuracy by combining it with another signature. Because the tumor cell proliferation status and the antitumor immunity status are considered important determinants for chemosensitivity, we speculated that the combination of an immune signature with a tumor cell proliferation signature would be able to predict pCR with greater accuracy. The GGI reflects the tumor cell proliferation status, and its association with pCR has been reported previously [25] . We demonstrated in our study that the combination of IRSN-23 and the GGI provides superior prediction of pCR in ER-positive tumors than either signature alone. In particular, this combination identified as many as 61% of the patients with ER-positive tumors who were very unlikely to achieve pCR ( pCR rate = 5%). From a clinical point of view, this information appears to be useful for the decision-making process regarding the indication of NAC for ER-positive tumors because patients with ER-positive tumors classified as Gp-NR with a low GGI, particularly those patients with clinically negative nodes, may be reasonable candidates not for NAC but for neoadjuvant hormonal therapy.
In conclusion, we were able to construct IRSN-23, which can predict the response to NAC with greater accuracy than the conventional parameters and independently of the intrinsic subtypes and chemotherapeutic regimens. Our results are consistent with the hypothesis that TILs play an important role in the response to chemotherapy. However, prospective studies are needed to confirm the clinical utility of funding
